Shares of DexCom, Inc. (NASDAQ:DXCM) rose 1.9% on Monday . The company traded as high as $49.16 and last traded at $49.85. Approximately 2,259,067 shares changed hands during mid-day trading, an increase of 96% from the average daily volume of 1,155,020 shares. The stock had previously closed at $48.92.

A number of research firms have commented on DXCM. Northland Securities cut DexCom from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $85.00 to $60.00 in a research note on Thursday. Robert W. Baird reaffirmed a “hold” rating and issued a $79.00 price objective on shares of DexCom in a research note on Sunday, September 10th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective (down from $85.00) on shares of DexCom in a research note on Thursday. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Finally, Cowen and Company reiterated a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. DexCom has a consensus rating of “Buy” and a consensus price target of $72.19.

The stock has a 50 day moving average of $72.62 and a 200-day moving average of $73.86. The stock’s market cap is $4.30 billion.

DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same quarter last year, the business earned ($0.24) EPS. The firm’s revenue was up 24.3% compared to the same quarter last year. On average, equities analysts anticipate that DexCom, Inc. will post ($0.79) earnings per share for the current fiscal year.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $69.34, for a total transaction of $416,040.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $69.47, for a total transaction of $100,731.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,223 shares of company stock valued at $2,285,138. Insiders own 1.70% of the company’s stock.

A number of hedge funds have recently modified their holdings of DXCM. FMR LLC lifted its stake in shares of DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after purchasing an additional 978,898 shares during the last quarter. Janus Henderson Group PLC boosted its stake in DexCom by 101,699.8% during the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after buying an additional 6,822,023 shares during the period. Vanguard Group Inc. boosted its stake in DexCom by 3.4% during the second quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after buying an additional 224,808 shares during the period. Baillie Gifford & Co. boosted its stake in DexCom by 1.4% during the first quarter. Baillie Gifford & Co. now owns 6,212,889 shares of the medical device company’s stock worth $526,418,000 after buying an additional 84,085 shares during the period. Finally, BlackRock Inc. boosted its stake in DexCom by 5.5% during the second quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after buying an additional 230,542 shares during the period.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/dexcom-inc-dxcm-stock-price-up-1-9/1603790.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.